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Summary
Objective: The aim of the present study was to investigate collagenmetabolism after anabolic and catabolic stimulation of chondrocytes ex vivo.
Design: Metabolic activities in ex vivo bovine cartilage explants were stimulated with insulin-like growth factor I (IGF-I) or a combination of
tumor necrosis factor alpha (TNFa) and oncostatin M (OSM). Supernatants were assessed for changes in biochemical markers, N-terminal
propeptide of type II (PIINP) collagen and fragments of C-telopeptide of type II collagen (CTX-II). Matrix metalloproteinases (MMP) were added
to metabolic inactivated cartilage and evaluated by the two biochemical markers for formation or degradation, respectively. Finally, urinary
CTX-II and PIINP were evaluated for assessment of type II collagen turnover in patients with rheumatoid arthritis (RA).
Results: In the bovine articular cartilage explants, IGF-I induced an increase in PIINP level up to 4.8 1.1 [ng/ml]/mg cartilage whereas CTX-II
remained below 0.1 0.1 [ng/ml]/mg cartilage. In the catabolic stimulated explants both PIINP and CTX-II were released to the supernatant,
reaching concentrations of 9.0 1.4 and 9.1 2.2 [ng/ml]/mg cartilage, respectively. RA patients had signiﬁcantly lower serum concentrations
of PIINP (3.4 3.7 ng/ml) compared with those healthy individuals (18.7 12.41 ng/ml, P< 0.001). In contrast, RA patients had signiﬁcantly
higher urinary CTX-II (0.8 0.8 mg/mmol) compared to the healthy controls (0.1 0.08 mg/mmol, P¼ 0.004).
Conclusions: This study is the ﬁrst to demonstrate that precursors and degradation products of type II collagen released into the supernatant
can effectively reﬂect the anabolic and catabolic activities of stimulated cartilage explants.
ª 2006 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Rheumatoid arthritis (RA) is a chronic inﬂammatory disease
that results in progressive joint destruction1. Invasive cells
like ﬁbroblasts, macrophages, and T and B cells are related
to the hyperplastic synovial tissue in joints causing an
increased production of effector molecules such as proin-
ﬂammatory cytokines and matrix degrading enzymes2.
The over expression of proteinases results in an imbalance
of these degrading enzymes and their inhibitors3,4 leading
to progressive destruction of joint tissue, including massive
erosion of articular cartilage.
The matrix in articular cartilage consists primarily of
proteoglycans and type II collagen5,6, the latter being cross-
linked in a network with collagen types IX and XI7,8. Type II
collagen is released during synthesis as procollagen
containing propeptides at both the amino and carboxy
termini, called N-terminal and C-terminal propeptide of
type II collagen (PIINP and PIICP). These propeptides are
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Received 7 April 2006; revision accepted 27 August 2006.33cleaved off by speciﬁc proteinases before deposition into
collagen ﬁbrils in the extracellular matrix (ECM)9e11.
Ex vivo studies of the pathogenesis RA and histological
investigation of cartilage erosion provide important semi-
quantitative information of the structural damage. In addi-
tion, quantiﬁcation of matrix metabolites in the supernatants
of ex vivo cartilage cultures can provide valuable infor-
mation of the underlying metabolic processes12. Articular
cartilage related biochemical markers such as YKL-40
and C-telopeptide fragments of type II collagen (CTX-II)
have both been included in ex vivo experiments and clinical
trials and therefore proven their effectiveness as powerful
predictors of disease progression and for assessment of
response to medical intervention13e15.
Degradation of type II collagen has been demonstrated in
cultures of bovine articular cartilage16,17, and recently it was
reported that circulating CTX-II fragments were observed in
collagen-induced arthritis of the rat as well as in subjects
with RA18,19.
Synthesis of type II collagen, however, has been less
systematically investigated in RA. Suppression of PIIANP,
the splice variant A of the N-terminal propeptide, was
reported in RA patients20, and Rebuck and coworkers
evaluated several immunoassays for PIINP and/or PIICP
in bovine pellet culture21. However, they did not detect
PIINP fragments in supernatants from these pellet cultures.5
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immunoassay for the detection of PIINP and subsequently
investigate changes of this biomarker during anabolic and
catabolic stimulation of bovine articular explants ex vivo.
Finally, we wanted to investigate whether measurement of
circulating PIINP either alone or in combination with
CTX-II could facilitate the identiﬁcation of patients with RA.
Methods
RA PATIENT POPULATION
Fifteen patients with RA according to the American
College of Rheumatology criteria for RA were recruited at
the Friedrich-Schiller University in Jena, Germany. Patients
were diagnosed with RA and treated with different combina-
tions and dosages of steroid and non-steroid anti-inﬂamma-
tory agents.
Disease activity at baseline was determined by evalua-
tion of X-ray pictures according to the Steinbrocker
method22 and scored 1e4. In addition, all patients were
positive for rheumatoid factors and typical rheumatical
nodes. Serum and urine samples were stored at 20C.
The distribution of the gender was 10 females and ﬁve
males with an age variation of 16e70 years. Furthermore,
the height and weight variations were 158e180 cm and
53e100 kg, respectively. Nine patients had rheumatoid
factor and the C-active protein level in serum was in the
range of 4.8e107.2 mg/l. For comparison, samples were
obtained from 15 healthy age- and sex-matched subjects.
The study was approved by the Ethical Committee of
Medical Faculty at Friedrich-Schiller University (Jena,
Germany e reference number 1019-01/03).
MATERIALS AND BUFFERS
All chemicals were purchased from either Sigma Aldrich
or Merck (Darmstadt, Germany) unless otherwise stated.
The synthetic peptides including biotin-conjugated deriva-
tives were from Pepceuticals Limited (Leicester, UK). Cell
culture reagents were obtained from either Gibco (Carlsbad,
US), BioVeris Corporation (Gaithersburg, US) or NUNC
(Rochester, US). Recombinant enzymes were purchased
from R&D Systems (Minneapolis, US). Phosphate-buffered
saline (PBS) solution was used as coating buffer.
DEVELOPMENT, SELECTION AND PURIFICATION
OF MONOCLONAL ANTIBODY (MAB)
Mice used for immunization were 8e10-week-old Balbc/A
strain. They were immunized subcutaneously with 200 ml of
an emulsion containing equal volume of incomplete
Freund’s adjuvant and the peptide GPQGPAGEQGPRGDR
(PIINP-I) conjugated to keyhole limpet hemocyanin (KLH)
(Pierce Biotechnology Inc., Rockford, US) corresponding
to 50 mg peptide conjugate per injection. Consecutive
immunizations were performed every second week during
the ﬁrst 6 weeks after which four additional immunizations
were made with 4-week intervals giving a total of seven
immunizations. Three days before isolation of the spleen
cells, mice were boosted intravenously with 50 mg PIINP-I
without Freund’s adjuvant. The fusion and cloning of hybrid-
oma cells were performed as described previously23.
Brieﬂy, the spleen cells from the selected mouse were
fused with Ag8X 63.653 myeloma cells in a ratio of 2:1 in
the presence of 47% polyethylene-glycerol (PEG) andcultured in medium containing 10% hybridoma cloning
factor (HCF) and selected by hypoxanthine aminopterinthy-
midine (HAT) medium. Supernatants were screened for
antibodies recognizing the synthetic peptide PIINP-I biotiny-
lated at the C-terminal end in an indirect enzyme-linked
immunoassay (ELISA). Further selection was based on
competitive binding to native PIINP in human serum.
Selected cell lines were cloned twice and propagated in
RPMI-1640 medium containing 10% fetal calf serum
(FCS). The mAbs were isolated from supernatants using
a Protein-G column (Amersham, Uppsala, Sweden). The
subclass of mAbs was determined by an isotyping kit
IsoStrip (Boehringer Mannheim, Munich, Germany). Perox-
idase (POD) labeled antibodies were prepared as advised
in the manufacture’s instructions (Roche, Basel, Switzer-
land). The mAb F7504 was used in the PIINP ELISA and
for puriﬁcation of native PIINP.
PURIFICATION OF NATIVE PIINP
PIINP was puriﬁed from synovial ﬂuid (SF) from several
young bovines (ages between 12 and 24 months) and
used for development of immunoassays. Ten milligrams
of puriﬁed mAb F7504 was coupled to CNBr-activated
Sepharose 4B (GE Healthcare, Chalfont St. Giles, UK) (ac-
tivated in 1 mM ice-cold HCl) in 0.1 M NaHCO3 couplings
buffer containing 0.5 M NaCl and rotated end-over-end for
24 h at 4C. The coupled antibody matrix was equilibrated
in 0.1 M TriseHCl and then packed in a C10/10 column.
SF was incubated with 5 units/ml hyaluronidase overnight
at 37C and then diluted ﬁve times in PBS buffer. Before
loading onto the column it was ﬁltered through a 45 mm ﬁlter
(Nalgene, Roskilde, Denmark). Bound PIINP was eluted
with 0.1 M GlycineHCl, pH 2.7 and neutralized with 1 M
TriseHCl, pH 9.
PIINP ELISA
The composition of the incubation buffer was 1.5 mM
KH2PO4, 8.5 mM Na2HPO42H2O, 2.7 mM KCl, 137 mM
NaCl, 10 g/l bovine serum albumin (BSA), 0.18 g/l Bronidox
(a preservative) (Cognis, Du¨sseldorf, Germany), 0.015 g/l
phenol red and 1 g/l Tween-20, pH 7.4. The maxisorp plate
(NUNC, Rochester, US) was passively coated with 1 ng/ml
puriﬁed native PIINP diluted in 100 ml PBS buffer overnight
without shaking at 4C. After coating, the plate was blocked
with PBS containing 5% BSA and washed ﬁve times with
PBS containing Tween-20 (washing buffer), 20 ml calibrator
(PIINP-I), control, and unknown samples were added into
the appropriate wells. Subsequently, 100 ml POD labeled
F7504 diluted to 160 ng/ml in incubation buffer was added
to the wells and incubated at 4C overnight with shaking
(300 rpm). After incubation the plate was washed ﬁve times
in washing buffer and 100 ml tetramethylbenzidine (TMB),
a chromogenic substrate (Kem-En-Tec, Denmark), was
pipetted into each well and incubated at 20C in dark with
shaking (300 rpm). Then 100 ml stopping solution (0.018 M
H2SO4) was added to the wells and the absorbance deter-
mined at 450 nm. The detection limit was deﬁned as the
concentration corresponding to the mean absorbance less
than three standard deviations (SD). The PIINP level
obtained in the bovine explant model was corrected for
the mass (per milligram cartilage tissue).
The intra-assay variation was determined on the basis of
21 determinations in one plate. The inter-assay determination
was established by 10 consecutive analytical runs, each
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determined by measuring three different bovine explant
samples. Samples were diluted with 1/5-fold increments.
QUANTIFICATION OF CARTILAGE DEGRADATION
Cartilage degradation was quantitatively investigated by
an immunoassay (PC-CartiLaps, Nordic Bioscience
Diagnostics, Herlev, Denmark) using mAbs recognizing
fragments of CTX-II. The CTX-II level obtained in the bovine
explant model was corrected for the mass of cultured
cartilage (per milligram cartilage tissue). Detection limit for
this was 0.2 ng/ml.
BONE MORPHOGENETIC PROTEIN 2 (BMP-2) ASSAY
The presence of BMP-2 in oncostatin M (OSM) and tumor
necrosis factor alpha (TNFa) stimulated bovine explants
was investigated by an immunoassay (R&D Systems,
Minneapolis, US), which employs mAbs to detect BMP-2
peptides.
EX VIVO MODELS OF CARTILAGE FORMATION
AND DEGRADATION
Bovine cartilage explants were isolated from knees
originating from the stiﬂe joints of heifers. Explants were
weighed (16 4 mg) and placed in 96-well plates and
incubated at 37C with 5% CO2 and shaking (50 rpm).
Serum-free Dulbecco’s Modiﬁed Eagle’s Medium contain-
ing high glucose (4500 ng/ml), 100 U/ml penicillin and
50 g/l streptomycin was used. Anabolic stimulated explants
were cultured in the presence of insulin-like growth factor I
(IGF-I)24,25 at 1e100 ng/ml. Catabolic stimulated explants
were incubated in the presence of 20 ng/ml OSM and
10 ng/ml TNFa18 with or without 10 mM of GM6001, a broad
spectrum matrix metalloproteinase (MMP) inhibitor. Meta-
bolic inactivated cartilage was included as a negative con-
trol and was prepared by three freezeethaw cycles in
frozen liquid N2
26. Six independent replicates were used
for each condition, and their supernatants were collected
and stored at 20C until further analysis.
MMP-MEDIATED RELEASE OF PIINP AND CTX-II
FROM METABOLIC INACTIVATED CARTILAGE
Metabolic inactivated bovine articular cartilage was
digested with MMP-3, -9 or -13, which are known to be
expressed in pathological cartilage tissue27. Brieﬂy, MMPs
were activated with 13.5 mM 4-aminophenyl mercuric
acetate (APMA) and diluted in 50 mM TriseHCl, pH 7.5,
150 mM NaCl, 10 mM CaCl2, 0.05 % Brij. The metabolic
inactivated cartilage was incubated overnight at 37C and
the proteolysis was stopped by adding 100 mM GM6001,
in three replicates.
STATISTICAL ANALYSIS
Results are shown as mean SD. Unpaired Student’s
t test was used to investigate whether there was a signiﬁcant
difference in biomarker release between stimulated and
unstimulated explants, or the serum concentration of
biomarkers between healthy subjects and RA patients.
For each of the RA patients the levels of PIINP and CTX-II
were expressed as Z-score. All data were log-transformed
before calculation of the Z-score. It was calculated as thedifference between the marker value of the RA patients
subtracted with the mean value of the healthy subjects,
and subsequently this difference was expressed in number
of SD of the control population (healthy subjects). The
Z-score for the accumulation index was calculated as the
difference between two marker Z-scores (Z-scorePIINP
Z-scoreCTX-II).
Results
ASSAY VALIDATION
mAb F7504 was raised against a linear peptide sequence
located in the center of PIINP and by virtue of its high afﬁnity
and speciﬁcity this clone was selected for assay develop-
ment. The antibodies were puriﬁed by Protein-G afﬁnity
chromatography and were determined to be the IgG1
subclass. The speciﬁcity was investigated by competitive
immunoassay. No cross-reactivity could be detected with
two selected peptides originating from the PIINP,
QDVRQPGPKG and GGPKGQKGEPGDIK, as well as
GPQPAGEQGPRGDR (PIINP-I) conjugated with biotin at
the C-terminal end (Fig. 1). Furthermore, the type I collagen
sequence, GFQGPAGE did not cross-react. The afﬁnity
estimated by IC50-value was 50.5 ng/ml and the coefﬁcient
of variations (CV in %) obtained from the intra- and inter-as-
say analyses were both less than 12% (Table I) and the
linearity was in the range of 100 11% (Table II).
CHANGES IN CHONDROCYTE FUNCTION INDUCED
BY ANABOLIC AND CATABOLIC PROCESSES
To drive chondrocytes into an anabolic or catabolic
function, bovine explants were either stimulated with IGF-I
or OSM and TNFa, respectively, and the cartilage metabo-
lism was investigated by evaluating supernatants in the
PIINP and CTX-II assays. Initially, cartilage explants were
incubated with different concentrations of IGF-I and after 5
days with change of conditioned media each day the PIINP
concentration was measured and was in the range of
1.2e3.0 [ng/ml]/mg cartilage for IGF-I doses of 1e100 ng/
ml (Fig. 2).
For further anabolic studies the intermediate 10 ng/ml
IGF-I concentration was selected. Conditioned media
were changed every second or third day and PIINP and
CTX-II concentrations per milligram cartilage in the
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Fig. 1. The speciﬁcity of the antibody F7504 was investigated by
inhibition of antibody binding to immobilized PIINP with different
synthetic peptides; QDVRQPGPKG (o) and GGPKGQKGEPGDIK
(>), both located within PIINP; QFQGPAGE (V) located within
the mature type I collagen; the immunogen (PIINP-I) conjugated
to biotin at the N-terminal end (D), and the calibrator (PIINP-I) (,).
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measured. PIINP concentration was signiﬁcantly higher in
IGF-I stimulated cultures compared to vehicle from day 12
[Fig. 3(A)]. In contrast, CTX-II release remained below
0.1 [ng/ml]/mg cartilage throughout the observation period
[Fig. 3(B)]. Combining the PIINP and the CTX-II data in
an accumulation index of type II collagen ([PIINP]/[CTX-
II]) demonstrated an increase from day 6 peaking at approx-
imately 500 at the end of the study [Fig. 3(C)].
In the bovine cartilage explants stimulated with OSM and
TNFa the conditioned media were changed every second or
third day and PIINP and CTX-II concentrations per milligram
cartilage in the collected supernatants at days 2, 5, 7, 9, 12,
14, 16 and 19 were measured. The PIINP concentration
was initially at 3.3 [ng/ml]/mg cartilage and decreased to
1.0 [ng/ml]/mg cartilage at day 9. In the late phase of
catabolic stimulation, PIINP increased to 9.1 [ng/ml]/mg
cartilage [Fig. 4(A)]. Applying the general MMP inhibitor,
GM6001, to the OSM and TNFa stimulated explants
resulted in a suppression of PIINP release to less than
0.5 [ng/ml]/mg cartilage in the late phase (data not shown).
CTX-II concentrations from TNFa and OSM stimulated
explants were less than 0.2 [ng/ml]/mg cartilage until day
9. After this time-point, the CTX-II level increased to
9.0 [ng/ml]/mg cartilage in the supernatant [Fig. 4(B)].
Also, CTX-II release was suppressed by GM6001 (data
not shown). The type II collagen accumulation index signif-
icantly decreased to approximately 1 at study termination
[Fig. 4(C)].
Since the production of PIINP was elevated in the
catabolic induced explants, it was relevant to investigate
Table I
Precision of the PIINP test. Data were obtained by repeated
measurements of supernatants from bovine cartilage explants.
For details, please refer to Methods
Intra-assay Inter-assay
Mean PIINP
concentration
(ng/ml)
CV
(%)
Mean PIINP
concentration
(ng/ml)
CV
(%)
Sample A 48.6 2.9 Sample D 22.8 11.9
Sample B 67.5 5.5 Sample E 37.8 6.6
Sample C 102.3 7.3 Sample F 118.5 9.0
Table II
Dilution recovery of the PIINP test. The linearity of the assay was
assessed by performing serial dilutions of supernatant from bovine
cartilage explants
Dilution Measured PIINP
concentration (ng/ml)
Recovery (%)
Sample G 5:5 39.9 100
4:5 30.3 105
3:5 23.7 101
2:5 16.5 97
Sample H 5:5 45.6 100
4:5 32.7 111
3:5 24.2 112
2:5 17.0 107
Sample I 5:5 36.4 100
4:5 27.8 104
3:5 21.4 102
2:5 14.5 100whether OSM and TNFa could stimulate chondrocytes to
produce BMP-2, as this molecule is known to stimulate
type II collagen production. Therefore, BMP-2 concentration
was quantiﬁed in the supernatant (Fig. 5). In the early
phase, i.e., before day 9 the BMP-2 concentration from
vehicle was undetectable whereas OSM and TNFa induced
explants contained 8.1 16.2 pg/ml of BMP-2. In the late
phase (after day 12), the catabolic stimulated explants
had increased level of BMP-2 at 66.8 49.0 pg/ml.
THE ROLE OF MMPS IN THE RELEASE OF PIINP AND CTX-II
FROM CARTILAGE EXPLANTS
Since both the PIINP and CTX-II levels were elevated in
catabolic stimulated explants it was subsequently investi-
gated, which proteases could cause this increment.
Metabolic inactivated cartilage was treated with different
MMPs, which were reported to be expressed in the ECM
and the supernatants were assessed for PIINP and CTX-II.
Treatment with MMP-3, -9 and -13 resulted in a minor PIINP
release of 7.6 1.6, 18.1 4.8 and 17.2 6.3 ng/ml, re-
spectively. The release of PIINP was completely
abrogated by GM6001 [Fig. 6(A)]. In contrast, a dramatic
increase in the CTX-II release was observed upon
incubation with MMP-9 and -13 (1294.4 81.1 and
4439.1 132.2 ng/ml) [Fig. 6(B)], which could be
suppressed with GM6001. Whereas the increase in PIINP
release caused by the MMPs was only about eight-fold
higher compared to the release of controls, the increase
in CTX-II release to MMP-9 and -13 was more than 1000-
fold higher than that of controls. To investigate the
biomarker levels retained in the tissue, bovine SF, origi-
nated from the same bovine as the metabolic inactivated
explants, was included. Measurements demonstrated high
levels of PIINP in SF (924.7 75.0 ng/ml) compared to
the release of metabolic inactivated cartilage caused by
recombinant MMPs. In contrast, CTX-II levels were rela-
tively low in SF (170.7 68.3 ng/ml). In addition, these
data were conﬁrmed in two experiments.
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Fig. 2. Dose-dependent stimulation by IGF-I of PIINP release from
bovine explants. The explants were stimulated with 1, 10 or 100 ng/
ml IGF-I in 5 days and PIINP was measured in the supernatant.
*¼P< 0.05.
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WITH DESTRUCTIVE JOINT DISEASE
To investigate whether these markers and the accumula-
tion index had any clinical relevance, serum and urine
samples from 15 RA patients in different stages of the
disease and healthy controls were measured in the PIINP
and CTX-II assays. The PIINP in serum from RA patients
was signiﬁcantly lower than in the control group (3.4 3.7
vs 18.7 12.41 ng/ml) [Fig. 7(A)]. In contrast, urinary
CTX-II was signiﬁcantly higher in RA patients (0.8
0.8 mg/mmol) compared to healthy subjects (0.1 0.08 mg/
mmol) [Fig. 7(B)]. To compare the performance of both
markers in discriminating between RA patients and healthy
persons the biochemical data were expressed in a Z-score.
In RA patients, the average Z-score was 1.5 and þ2.6 for
PIINP and CTX-II, respectively, while the average Z-score
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Fig. 3. Bovine explants were stimulated with 10 ng/ml IGF-I (C)
or vehicle (B) and the PIINP (A) and CTX-II (B) were measured.
The accumulation index ([PIINP]/[CTX-II]) (C) was calculated for
the IGF-I stimulated explants. * ¼P < 0.05, ** ¼P < 0.01 and
***¼ P< 0.001.of the accumulation index was 4.1 (Z-scorePIINP Z-
scoreCTX-II) [Fig. 7(C)].
Discussion
The main ﬁnding of this study is that the anabolic or
catabolic state of chondrocytes ex vivo is effectively
reﬂected by the metabolism of type II collagen quantiﬁed
by biomarkers in the supernatant. Release of degradation
fragments and precursors by immunoassays allows calcula-
tion of a biochemical index indicative for the actual chondro-
cyte function. To our knowledge, this is the ﬁrst time that
PIINP has been quantitatively determined in supernatant
bovine cartilage explants. In addition, preliminary data
reported here suggest that combined measurements of
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Fig. 4. Bovine explants were stimulated with 10 ng/ml TNFa and
20 ng/ml OSM (C) or vehicle (B) and the PIINP (A) and CTX-II
(B) levels in the supernatant were measured. The accumulation in-
dex ([PIINP]/[CTX-II]) (C) was calculated for the TNFa and OSM
stimulated explants. *¼P< 0.05 and ***¼ P< 0.001.
340 A. K. Olsen et al.: Collagen metabolism after anabolic and catabolic stimulation of chondrocytesPIINP and CTX-II have potential for the identiﬁcation of
patients with destructive joint diseases.
Progression of osteoarthritis (OA) and RA is partly
determined by the balance between catabolic and anabolic
processes in the joint. Since articular cartilage is an avascu-
lar tissue stimulation of the local chondrocytes is responsi-
ble for maintaining and repairing the ECM. For the
investigation of these processes, explants from articular
cartilage provide a relevant and convenient approach.
One of the advantages of using articular cartilage is a close
in vivo likeness, compared to other in vitro models15.
Whereas the immunodetection of collagen fragments
originating from degradation of cartilage has been the
subject of many studies, the utility of measuring propeptides
of type II collagen has been less thoroughly investigated.
The strategy employed in the present study resulted in
the identiﬁcation of an antibody that recognize an abundant
propeptide species in the context of a neo-epitope, i.e., the
reactivity of the antibody is dependent upon the exposure of
a free N-terminal Glycine in the sequence GPQGPA-
GEQGPRGDR. This mAb (F7504) was incorporated into
a competition immunoassay and subsequently used for
quantiﬁcation of PIINP in culture supernatants and human
serum.
Here we report an elevation in the release of PIINP into
the culture supernatant from bovine cartilage explant
cultures stimulated for more than 9 days with IGF-I. Under
these conditions the degradation of type II collagen, as
determined by the release of CTX-II, remained low, and
therefore the accumulation index (PIINP/CXT-II) increased
to approximately 500 at study termination. On the contrary,
the accumulation index approached 1 in supernatants
derived from cartilage explants stimulated with OSM and
TNFa. This large dynamic window suggests that the
biochemical index reﬂecting the balance between anabolic
and catabolic processing of type II collagen might be useful
in the assessment of chondrocyte function. The catabolic
cultures were prolonged to day 19, to obtain reasonable
induction of collagen type II degradation16. Almost no
collagen type II degradation can be observed before day
14 in the bovine articular explant model, as previously
published under other experimental and similar
settings13,16.
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Fig. 5. BMP-2 levels were determined in the supernatants of OSM
and TNFa stimulated bovine cartilage explants (gray bars) or
vehicle (black bars), and expressed as the average concentration
in the early phase (days 0e9) and late phase (days 12e19),
respectively. T¼ TNFa; n.s.¼ none signiﬁcant. *¼P< 0.05.As detection in the PIINP assay is dependent upon the
exposure of a free N-terminus of the propeptide, and inhibi-
tion of proteases by GM6001 in the catabolic explant culture
resulted in complete abrogation of PIINP release into the
supernatant, it was investigated if MMPs were directly
involved in the release of PIINP from inactivated explants,
i.e., from ECM. From the in vitro experiment, the data
suggested that MMP-3, MMP-9 and MMP-13 only had a lim-
ited capability to release PIINP from the ECM, whereas the
release of CTX-II was dramatically increased in the
presence of these proteases, in particular with MMP-13.
Therefore, the release of PIINP into the supernatant might
involve other proteases, e.g., MMP-8, or a disintegrin and
metalloprotease and a disintegrin and metalloprotease
with thrombospondin motif, contributing to the processing
of this analyte and the generation of the N-terminal neo-
epitope. Fukui and co-workers28 have recently demon-
strated that PIINP has several MMP cleavage sites and
some of them are susceptible for more than one subclass
of MMPs. In addition, the high PIINP level in SF compared
to the PIINP retained in the metabolic inactivated cartilage
could indicate that the incorporation of PIINP in ECM is
relatively low, which is in accordance to other studies29. In
contrast, the mature type II collagen is primarily incorporated
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Fig. 6. MMP dependent release of PIINP (A) and CTX-II (B) was
investigated in the presence or absence of broad spectrum MMP
inhibitor, GM6001. The proteases were incubated for 24 h with
metabolic inactivated cartilage. For comparison, markers were
determined in bovine SF.
341Osteoarthritis and Cartilage Vol. 15, No. 3into the ECM and is only released as fragments to the
SF in the presence of protease activity7,8,27. Therefore,
the high release of CTX-II caused by MMPs compared
to the relatively low PIINP release from the cartilage
explants could either be due to involvement of other
MMPs than the ones investigated here or be due to low
content of PIINP in cartilage compared to mature type II
collagen.
Our data seem to support the notion, that the release of
PIINP is primarily dependent on synthesis of new collagen
and secondly on the processing of the propeptides before
release into the supernatant of cultures ex vivo. IGF-I
stimulates synthesis of type II collagen by chondrocytes,
and this is reﬂected in the increase in PIINP and the
suppression of CTX-II. The catabolic stimulated explants,
however, gave rise to increased levels of PIINP. It has
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Fig. 7. Serum PIINP (A) and urinary CTX-II (B) were determined in
healthy subjects (n ¼ 15) and in patients with RA (n ¼ 15). In
addition, the Z-scores (C) for PIINP, CTX-II and accumulation index
in 15 patients with RA were calculated. Lines represented the mean
Z-score. For calculation of Z-scores please refer to Statistical
analysis.been reported that TNFa stimulates intra-cellular production
of type II collagen via a BMP-2 mediated mechanism30,31.
This is consistent with the present observation of increased
PIINP release from TNFa stimulated cartilage explants. In
contrast, the release of CTX-II is dependent upon an upre-
gulation of MMP activity, in particular MMP-9 and -1317.
The relevance of these ex vivo experiments to cartilage
metabolism in vivo was investigated by comparing
biochemical marker levels in the serum between healthy
individuals and RA patients. A hallmark of RA is aggressive
degradation of the ECM caused by elevated levels of
proinﬂammatory cytokines. In accordance to this we found
a dramatic elevation of CTX-II in these RA patients reﬂect-
ing the degradation of type II collagen. This is in agreement
with a previous prospective study where the CTX-II level is
signiﬁcantly increased in an early RA population relative to
baseline levels32. The decreased circulating levels of PIINP
relative to healthy controls seem to be in line with a limited
repair function of articular cartilage33,34, and have
previously been reported for PIIANP20. Decrease of PIINP
and elevation of CTX-II in these patients furthermore
support that different metabolic pathways are involved in
the release of these two markers of collagen synthesis
and degradation, respectively.
In conclusion, the data suggest that the combination of
the PIINP and the CTX-II marker might be useful in the
quantitative assessment of the balance between the
catabolic and the anabolic activities of the articular
chondrocytes. Furthermore, as both assays are applicable
for human specimen, they may ultimately give useful
information in an evaluation of medical intervention for the
treatment and prevention of destructive joint disease.
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